| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
|
Ann Oncol
|
2010
|
2.64
|
|
2
|
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
|
Ann Oncol
|
2012
|
2.16
|
|
3
|
Role of diaphragmatic surgery in 69 patients with ovarian carcinoma.
|
Int J Gynecol Cancer
|
2008
|
2.12
|
|
4
|
Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes.
|
J Pharm Sci
|
1997
|
1.62
|
|
5
|
Prevalence of HIV antibody and pregnancy in Tayside, 1984-9: background to screening.
|
BMJ
|
1990
|
1.61
|
|
6
|
Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
|
Ann Oncol
|
2005
|
1.54
|
|
7
|
Longitudinal hysteroscopic follow-up during tamoxifen treatment.
|
Lancet
|
1998
|
1.42
|
|
8
|
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
|
Ann Oncol
|
2013
|
1.41
|
|
9
|
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
|
J Clin Pathol
|
2005
|
1.33
|
|
10
|
Timing of debulking surgery in advanced ovarian cancer.
|
Int J Gynecol Cancer
|
2008
|
1.27
|
|
11
|
Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma.
|
Br J Cancer
|
2007
|
1.21
|
|
12
|
Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.
|
Ann Oncol
|
2005
|
1.19
|
|
13
|
Endometrial lesions in patients undergoing tamoxifen therapy.
|
Int J Gynaecol Obstet
|
1991
|
1.12
|
|
14
|
Different outcome variables yield different results!
|
Ann Oncol
|
2012
|
1.06
|
|
15
|
Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
|
J Clin Pathol
|
2009
|
1.04
|
|
16
|
The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment.
|
Gynecol Oncol
|
2010
|
1.04
|
|
17
|
Tamoxifen and the uterus and endometrium.
|
Lancet
|
1989
|
1.01
|
|
18
|
A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.
|
Eur J Cancer
|
1996
|
1.00
|
|
19
|
Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers.
|
Ann Oncol
|
2012
|
0.97
|
|
20
|
Management of menopausal symptoms in breast cancer patients.
|
Maturitas
|
2010
|
0.95
|
|
21
|
Lack of genotoxicity of tamoxifen in human endometrium.
|
Cancer Res
|
1996
|
0.93
|
|
22
|
Prevention of breast cancer.
|
Lancet
|
1993
|
0.93
|
|
23
|
Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia.
|
Int J Gynecol Cancer
|
2006
|
0.92
|
|
24
|
Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.
|
Oncogene
|
2008
|
0.92
|
|
25
|
Invasive adenocarcinoma arising in extramammary Paget's disease of the vulva.
|
Histopathology
|
1991
|
0.90
|
|
26
|
Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs.
|
Breast Cancer Res Treat
|
2010
|
0.90
|
|
27
|
Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma.
|
Int J Gynecol Cancer
|
2005
|
0.88
|
|
28
|
Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up.
|
Ann Oncol
|
2011
|
0.88
|
|
29
|
Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.
|
Gynecol Oncol
|
2013
|
0.88
|
|
30
|
Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer.
|
Gynecol Oncol
|
2009
|
0.88
|
|
31
|
Measurement of urinary beta core fragment of human chorionic gonadotrophin in women with vulvovaginal malignancy and its prognostic significance.
|
Br J Cancer
|
1995
|
0.88
|
|
32
|
Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.
|
Breast Cancer Res Treat
|
2008
|
0.88
|
|
33
|
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
|
Ann Oncol
|
2013
|
0.88
|
|
34
|
Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium.
|
Carcinogenesis
|
1999
|
0.87
|
|
35
|
The prognostic significance of urinary beta core fragment in premenopausal women with carcinoma of the cervix.
|
Gynecol Oncol
|
1994
|
0.87
|
|
36
|
Activity of fulvestrant in HER2-overexpressing advanced breast cancer.
|
Ann Oncol
|
2009
|
0.87
|
|
37
|
Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
|
Breast Cancer Res Treat
|
2013
|
0.86
|
|
38
|
Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients.
|
Int J Gynecol Cancer
|
2006
|
0.86
|
|
39
|
Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers.
|
Ann Oncol
|
2013
|
0.86
|
|
40
|
Laparoscopic para-aortic lymphadenectomy and positron emission tomography scan as staging procedures in patients with cervical carcinoma stage IB2-IIIB.
|
Int J Gynecol Cancer
|
2007
|
0.86
|
|
41
|
Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.
|
Acta Clin Belg
|
2009
|
0.85
|
|
42
|
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
|
Ann Oncol
|
2011
|
0.85
|
|
43
|
Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases.
|
Eur J Cancer
|
2013
|
0.85
|
|
44
|
Tamoxifen and the uterus.
|
BMJ
|
1994
|
0.84
|
|
45
|
Breast cancer prevention: lifestyle changes and chemoprevention.
|
Acta Clin Belg
|
2011
|
0.83
|
|
46
|
A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative.
|
Ann Oncol
|
2012
|
0.83
|
|
47
|
Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.
|
Ann Oncol
|
2012
|
0.83
|
|
48
|
Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring.
|
Eur J Obstet Gynecol Reprod Biol
|
2002
|
0.82
|
|
49
|
PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer.
|
Gynecol Oncol
|
2013
|
0.82
|
|
50
|
False-negative tests in breast cancer management.
|
Neth J Med
|
2011
|
0.82
|
|
51
|
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
|
Breast Cancer Res Treat
|
2014
|
0.81
|
|
52
|
The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers.
|
Breast
|
2013
|
0.81
|
|
53
|
Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age.
|
Breast Cancer Res Treat
|
2007
|
0.81
|
|
54
|
Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients.
|
Breast Cancer Res Treat
|
2011
|
0.81
|
|
55
|
Inhibitory effect of curcuminoids and tetrahydrocurcuminoids on equine activated neutrophils and myeloperoxidase activity.
|
Physiol Res
|
2007
|
0.81
|
|
56
|
Synthesis and biological evaluation of new 3-aralkylamino-2-aryl-2H-1, 2,4-pyridothiadiazine 1,1-dioxides as potential CCK-receptor ligands.
|
J Pharm Pharmacol
|
1997
|
0.80
|
|
57
|
Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer.
|
Tumour Biol
|
2008
|
0.80
|
|
58
|
Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen.
|
Cancer Res
|
1998
|
0.80
|
|
59
|
Matrix metalloproteinase expression patterns in luminal A type breast carcinomas.
|
Dis Markers
|
2007
|
0.80
|
|
60
|
Short-Term Prognostic Index for Breast Cancer: NPI or Lpi.
|
Patholog Res Int
|
2010
|
0.79
|
|
61
|
Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables.
|
Clin Exp Metastasis
|
2005
|
0.79
|
|
62
|
Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
|
Ann Oncol
|
2010
|
0.79
|
|
63
|
The oestrogen receptor and its selective modulators in gynaecological and breast cancer.
|
Eur J Cancer
|
2000
|
0.79
|
|
64
|
Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
|
Br J Cancer
|
2009
|
0.79
|
|
65
|
Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
|
Breast Cancer Res Treat
|
2014
|
0.78
|
|
66
|
Inhalation with NDS27 attenuates pulmonary neutrophilic inflammation in recurrent airway obstruction.
|
Vet Rec
|
2011
|
0.78
|
|
67
|
Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology.
|
Ultrasound Obstet Gynecol
|
2010
|
0.78
|
|
68
|
Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
|
Climacteric
|
2015
|
0.78
|
|
69
|
Raloxifene effect on frequency of surgery for pelvic floor relaxation.
|
Obstet Gynecol
|
2001
|
0.77
|
|
70
|
Endometrial changes in patients on tamoxifen.
|
Lancet
|
1995
|
0.77
|
|
71
|
Modulation of endometrial transforming growth factor beta (TGFbeta) by tamoxifen.
|
Eur J Cancer
|
2000
|
0.77
|
|
72
|
Wilms' tumour gene 1 (WT1) positivity in endothelial cells surrounding epithelial uterine tumours.
|
Histopathology
|
2009
|
0.77
|
|
73
|
Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer.
|
Int J Gynecol Cancer
|
2007
|
0.77
|
|
74
|
Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.
|
Int J Gynecol Cancer
|
2006
|
0.77
|
|
75
|
Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study.
|
J Pharm Belg
|
1999
|
0.76
|
|
76
|
Endocrine treatment and prevention of breast and gynaecological cancers.
|
Eur J Cancer
|
2002
|
0.76
|
|
77
|
Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.
|
Cardiovasc Drug Rev
|
2001
|
0.76
|
|
78
|
Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy.
|
Br J Obstet Gynaecol
|
1990
|
0.76
|
|
79
|
Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood.
|
Prostaglandins Leukot Essent Fatty Acids
|
2001
|
0.76
|
|
80
|
Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports.
|
Gynecol Obstet Invest
|
2008
|
0.76
|
|
81
|
Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function.
|
Prostaglandins Leukot Essent Fatty Acids
|
2000
|
0.75
|
|
82
|
Endometrial changes in patients receiving tamoxifen therapy.
|
N Y State J Med
|
1991
|
0.75
|
|
83
|
Effects of tamoxifen on uterus.
|
Lancet
|
1994
|
0.75
|
|
84
|
Tamoxifen-induced endometrial polyp.
|
N Engl J Med
|
1997
|
0.75
|
|
85
|
The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen.
|
Ann Oncol
|
2013
|
0.75
|
|
86
|
A controlled clinical study on tamoxifen and the endometrium.
|
Gynecol Oncol
|
1994
|
0.75
|
|
87
|
Effect of tamoxifen on bone.
|
BMJ
|
1993
|
0.75
|
|
88
|
Reply to the Letter to the Editor on "Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients", by I. Cohen Ann Oncol 2005; 16: 1399.
|
Ann Oncol
|
2005
|
0.75
|
|
89
|
Which questionnaire to measure psychosocial effects of having an abnormal PAP smear?
|
J Clin Epidemiol
|
1996
|
0.75
|
|
90
|
BM 144: an original thromboxane A2 receptor antagonist derived from torasemide.
|
J Pharm Belg
|
1999
|
0.75
|
|
91
|
The immunocytochemical versus cytosol measurement of the oestrogen receptor in invasive breast cancer tissue.
|
Eur J Cancer
|
2000
|
0.75
|
|
92
|
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
|
Breast Cancer Res Treat
|
2009
|
0.75
|
|
93
|
Effect of cancer prevalence on the use of risk-assessment cut-off levels and the performance of mathematical models to distinguish malignant from benign adnexal masses.
|
Ultrasound Obstet Gynecol
|
2011
|
0.75
|
|
94
|
The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer.
|
Cancer Treat Res
|
2007
|
0.75
|
|
95
|
How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years?
|
Acta Clin Belg
|
2014
|
0.75
|
|
96
|
The position of neoadjuvant chemotherapy within the treatment of ovarian cancer.
|
Minerva Ginecol
|
2006
|
0.75
|
|
97
|
Tamoxifen and the uterus.
|
Eur J Cancer
|
1998
|
0.75
|
|
98
|
An unusual type of endometrial cancer, related to tamoxifen?
|
Eur J Obstet Gynecol Reprod Biol
|
1992
|
0.75
|
|
99
|
Usefulness of urodynamic investigations in female incontinence.
|
Eur J Obstet Gynecol Reprod Biol
|
1992
|
0.75
|
|
100
|
Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: An analysis of 208 patients.
|
Int J Gynecol Cancer
|
2006
|
0.75
|
|
101
|
Pyridothiadiazinedioxides structurally related to quinazolinones cholecystokinin/gastrin receptor ligands: synthesis and biological evaluation.
|
Eur J Pharm Sci
|
1998
|
0.75
|
|
102
|
The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses.
|
Gynecol Oncol
|
1993
|
0.75
|
|
103
|
Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium.
|
Eur J Cancer Care (Engl)
|
2014
|
0.75
|
|
104
|
Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients.
|
Int J Gynecol Cancer
|
2006
|
0.75
|
|
105
|
Endometrial cancer: predictors of response and preferred endocrine therapy.
|
Int J Gynecol Cancer
|
2006
|
0.75
|